The Pharmaceutical Market: Belgium

Date: March 1, 2013
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P61F40ADF72EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Belgium
The report is to be ready for Q2 2013

OVERVIEW OF THE PHARMACEUTICAL MARKET IN BELGIUM

We remain less than optimistic about the short- term growth of the Belgian pharmaceutical market. Through to 2016, the market's value is expected to post a negative compound annual growth rate (CAGR) of -1% in both local currency and US dollar terms, largely on account of cost containment measures and patent expirations. Nevertheless, foreign companies are expected to continue using Belgian pr oduction sites for exports, the country also being a popular re-export source.

Headline Expenditure Projections

Pharmaceuticals: EUR6.12bn (US$8.51bn) in 2011 to EUR5.96bn (US$7.57bn) in 2012; -2.6% in local currency terms and -11.0% in US dollar terms. Local currency forecast broadly unchanged from Q412.

Healthcare: EUR38.96bn (US$54.15bn) in 2011 to EUR40.05bn (US$50.86bn) in 2012; +2.8% in local currency terms and -6.1% in US dollar terms. Local currency forecast broadly unchanged from Q412.

Medical devices: EUR1.67bn (US$2.32bn) in 2011 to EUR1.74bn (US$2.21bn) in 2012; +4.2% in local currency terms and -4.8% in US dollar term s. Local currency forecast unchanged from Q412.

Risk/Reward Rating: Belgium is again ranked sixth out of 10 countries in Western Europe, with its risks and rewards scores virtually mirroring the regional average. Despite the well-developed nature of the market, including the high consumption of patented medicines, growth in the coming years will be moderated by factors such as cost containment initiatives and patent expirations.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Belgium Pharmaceuticals And Healthcare Industry SWOT
    Belgium Political SWOT
    Belgium Economic SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Western Europe Pharmaceutical And Healthcare Risk/Reward Ratings, Q113
    Rewards
    Risks

BELGIUM – MARKET SUMMARY

REGULATORY REGIME

    Table: Applications Received And Processed By AFMPS, 2007-2009
    Table: Authorised Pharmaceuticals, 2002-2008
    Pharmaceutical Advertising
    Regulatory Developments
    Intellectual Property Environment
    Pricing Regime
    Price Cuts
    Reimbursement Regime
    Table: Reimbursements By Category, 2009
    Table: Leading Products Reimbursed By Public Insurance By Active Substance, 2010
    Generic Medicines Sector
    OTC Medicines Sector
    Table: Price Build-Up For OTC Medicines

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Public Health Developments
    Healthcare Sector
    Healthcare Insurance
    Healthcare Financing
    Medical Tourism
    Research & Development Sector
    Table: R&D Investment By Chemical & Life Science Industries, 2005-2010
    Clinical Trials
    Medical Device Market

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales, 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure, 2008-2016
    Table: Government Healthcare Expenditure, 2008-2016
    Table: Private Healthcare Expenditure, 2008-2016
      Key Growth Factors – Macroeconomic
      Prescription Drug Market Forecast
      Table: Prescription Drug Sales, 2008-2016
      Table: Reimbursable Ambulatory Prescriptions By Therapeutic Category, 2006-2009 (Euros 000s)
      Table: Top 25 Active Ingredients In Reimbursable Ambulatory Prescriptions, 2009
      Patented Drug Market Forecast
      Table: Patented Drug Sales, 2009-2016
      Generic Drug Market Forecast
      Table: Generic Companies By Market Share, 2010
      Table: Generic Drug Sales, 2008-2016
      OTC Medicine Market Forecast
      Table: OTC Medicine Sales, 2008-2016
      Pharmaceutical Trade Forecast
      Table: Pharmaceutical Trade, 2008-2016
      Medical Device Market Forecast
      Table: Medical Device Sales, 2008-2016
      Other Healthcare Data Forecasts
      Key Risks To BMI’s Forecasts

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Member Companies Of Pharma.be, 2011
      Company Developments
      Pharmaceutical Wholesale
      Table: Members Of AnGR, 2011
      Pharmaceutical Retail
      Table: Members Of OPHACO, 2011

COMPANY PROFILES

  Local Companies
      UCB Pharma
      Solvay (Abbott)
      Janssen Pharmaceutica
      Omega Pharma
      Galapagos
  Multinational Companies
      GlaxoSmithKline
      Pfizer
      Novartis
      Sanofi
      Merck & Co

DEMOGRAPHIC OUTLOOK

      Table: Population By Age Group, 1990-2020 (‘000)
      Table: Population By Age Group, 1990-2020 (% of total)
      Table: Key Population Ratios, 1990-2020
      Table: Rural/Urban Population Split, 1990-2020

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts

PHARMACEUTICAL RISK/REWARD RATINGS METHODOLOGY

RATINGS OVERVIEW

TABLE: PHARMACEUTICAL RISK/REWARD INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


The Pharmaceutical Market: Chile US$ 1,295.00 Jan, 2013 · 141 pages
The Pharmaceutical Market: China US$ 1,295.00 Jan, 2013 · 118 pages
The Pharmaceutical Market: Colombia US$ 1,295.00 Jan, 2013 · 114 pages
The Pharmaceutical Market: Croatia US$ 1,295.00 Jan, 2013 · 86 pages

Ask Your Question

The Pharmaceutical Market: Belgium
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: